Skip to main content

Advertisement

SpringerLink
Log in

Treatment-related symptom management in patients with multiple myeloma: a review

  • Review Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

Recent therapeutic advancements have significantly improved overall survival of patients with multiple myeloma (MM). As a result, the impact of disease- and treatment-related symptoms must be managed effectively to improve patient quality of life, given prolonged survival after diagnosis. This review discusses current MM treatment options, effective symptom management approaches, and practical strategies for supportive care.

Methods

A literature search was performed using MEDLINE/PubMed and scientific congress databases, focusing on clinical trials, review articles, clinical practice guidelines, and other guidance documents on treatment paradigms and supportive care strategies in MM. Additionally, clinical practice worksheets were developed from published sources, and nursing “pearls of wisdom” were gathered from practical experience in the clinic.

Results

Current therapeutic regimens for relapsed/refractory MM include proteasome inhibitors (i.e., bortezomib, carfilzomib) and immunomodulatory agents (i.e., thalidomide, lenalidomide, pomalidomide), alone or in combination with chemotherapy or corticosteroids. Toxicities associated with agents and combination regimens used in the treatment of MM include myelosuppression, venous thromboembolism, peripheral neuropathy, infections, fatigue, gastrointestinal disorders, and/or cardiac events. Treatment-specific tools and clinical assessments can be useful for optimizing dosing and schedule adjustments to increase therapy duration, and implementing supportive care strategies (e.g., growth factors, transfusional support, intravenous hydration, bisphosphonates, antiviral therapies) to manage treatment-related symptoms.

Conclusions

Improved survival after MM diagnosis has led to increased patient susceptibility to other diseases and comorbidities due to advanced age. In addition to appropriate drug dosing and administration, effective supportive care and health maintenance are crucial for maximizing quality of life and disease control.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Collins CD (2005) Problems monitoring response in multiple myeloma. Cancer Imaging 5 Spec No A:S119-26

  2. Katzel JA, Hari P, Vesole DH (2007) Multiple myeloma: charging toward a bright future. CA Cancer J Clin 57:301–318

    Article  PubMed  Google Scholar 

  3. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102:1115–1123

    Article  CAS  PubMed  Google Scholar 

  4. Kyle RA, Rajkumar SV (2009) Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma 9:278–288

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (2013) SEER cancer statistics review, 1975–2010. National Cancer Institute

  6. Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Kristinsson SY, McGlynn KA, Landgren O (2010) Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 116:5501–5506

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. San-Miguel JF, Paiva B, Gutierrez NC (2013) New tools for diagnosis and monitoring of multiple myeloma. Am Soc Clin Oncol Educ Book 313–318

  8. Jakubowiak A (2012) Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives. Semin Hematol 49(Suppl 1):S16–S32

    Article  PubMed  Google Scholar 

  9. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516–2520

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Snowden JA, Ahmedzai SH, Ashcroft J, D’Sa S, Littlewood T, Low E, Lucraft H, Maclean R, Feyler S, Pratt G, Bird JM, Haemato-oncology Task Force of British Committee for Standards in Haematology and UK Myeloma Forum (2011) Guidelines for supportive care in multiple myeloma 2011. Br J Haematol 154:76–103

    Article  CAS  PubMed  Google Scholar 

  11. Bird JM, Owen RG, D’Sa S, Snowden JA, Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F, Morgan G, Cavenagh J, Low E, Behrens J, Haemato-oncology Task Force of British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum (2011) Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 154:32–75

    Article  CAS  PubMed  Google Scholar 

  12. National Comprehensive Cancer Network (2014) NCCN clinical practice guidelines in oncology, multiple myeloma V2.2014

  13. Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Blade J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen HE, Kroeger N, Gahrton G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BG, San Miguel J, Lonial S, International Myeloma Working Group (2011) International myeloma working group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 117:6063–6073

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, Kumar S, Hajek R, Giralt S, Bringhen S, Anderson KC, Richardson PG, Cavo M, Davies F, Blade J, Einsele H, Dimopoulos MA, Spencer A, Dispenzieri A, Reiman T, Shimizu K, Lee JH, Attal M, Boccadoro M, Mateos M, Chen W, Ludwig H, Joshua D, Chim J, Hungria V, Turesson I, Durie BG, Lonial S, IMWG (2009) International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 23:1716–1730

    Article  CAS  PubMed  Google Scholar 

  15. International Myeloma Foundation (2012) Multiple myeloma: the patient journey through survivorship. Oncology Nursing Society’s (ONS) 37th Annual Congress

  16. American Cancer Society (2013) Multiple myeloma. http://www.cancer.org/cancer/multiplemyeloma/detailedguide/index. Accessed 22 May 2014

  17. Hideshima T, Richardson PG, Anderson KC (2011) Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther 10:2034–2042

    Article  CAS  PubMed  Google Scholar 

  18. Millenium Pharmaceuticals (2012) VELCADE prescribing information

  19. Argyriou AA, Iconomou G, Kalofonos HP (2008) Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 112:1593–1599

    Article  CAS  PubMed  Google Scholar 

  20. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12:431–440

    Article  PubMed  Google Scholar 

  21. Moreau P, Coiteux V, Hulin C, Leleu X, van de Velde H, Acharya M, Harousseau JL (2008) Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica 93:1908–1911

    Article  CAS  PubMed  Google Scholar 

  22. Hrusovsky I, Emmerich B, von Rohr A, Voegeli J, Taverna C, Olie RA, Pliskat H, Frohn C, Hess G (2010) Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland. Oncology 79:247–254

    Article  CAS  PubMed  Google Scholar 

  23. Petrucci MT, Giraldo P, Corradini P, Teixeira A, Dimopoulos MA, Blau IW, Drach J, Angermund R, Allietta N, Broer E, Mitchell V, Blade J (2013) A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol 160:649–659

    Article  CAS  PubMed  Google Scholar 

  24. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL (2012) Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120:947–959

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Gay F, Palumbo A (2010) Management of disease- and treatment-related complications in patients with multiple myeloma. Med Oncol 27(Suppl 1):S43–S52

    Article  CAS  PubMed  Google Scholar 

  26. Delforge M, Blade J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, Palumbo A, Van Damme P, San-Miguel JF, Sonneveld P (2010) Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 11:1086–1095

    Article  CAS  PubMed  Google Scholar 

  27. Onyx Pharmaceuticals (2012) KRYPOLIS prescribing information

  28. Dytfeld D, Jasielec J, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R, Jakubowiak AJ (2014) Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica 99:e162–164

  29. Fostier K, De Becker A, Schots R (2012) Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma. Onco Targets Ther 5:237–244

    PubMed Central  CAS  PubMed  Google Scholar 

  30. Singhal S, Siegel DS, Martin T, Vij R, Wang L, Jakubowiak AJ, Lonial S, Kuketi V, Zonder JA, Wong AF, McCulloch L, Bardos AZ, Niesvizky R, Orlowski RZ, Stewart AK, Kotlovker D, Jagannath S (2011) Integrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis. Blood 118:abstr 1876

  31. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S (2012) A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120:2817–2825

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Latif T, Chauhan N, Khan R, Moran A, Usmani SZ (2012) Thalidomide and its analogues in the treatment of multiple myeloma. Exp Hematol Oncol 1:27-3619-1-27

    Article  Google Scholar 

  33. Celgene (2013) THALDOMID prescribing information

  34. Palumbo A, Facon T, Sonneveld P, Blade J, Offidani M, Gay F, Moreau P, Waage A, Spencer A, Ludwig H, Boccadoro M, Harousseau JL (2008) Thalidomide for treatment of multiple myeloma: 10 years later 111:3968–3977

  35. Lonial S, Mitsiades CS, Richardson PG (2011) Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res 17:1264–1277

    Article  PubMed  Google Scholar 

  36. Celgene (2013) REVLIMID prescribing information

  37. Yang B, Yu RL, Chi XH, Lu XC (2013) Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. PLoS One 8:e64354

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Bringhen S, Gay F, Pautasso C, Cerrato C, Boccadoro M, Palumbo A (2012) Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma. Expert Opin Drug Metab Toxicol 8:1209–1222

    Article  CAS  PubMed  Google Scholar 

  39. Faiman B (2013) Nursing considerations for patients with multiple myeloma. Clin Care Opt Oncol

  40. Celgene (2014) POMALYST precribing information

  41. Chanan-Khan AA, Swaika A, Paulus A, Kumar SK, Mikhael JR, Rajkumar SV, Dispenzieri A, Lacy MQ (2013) Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J 3:e143

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Ocio EM, Mateos MV, San-Miguel JF (2012) Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs. Expert Opin Investig Drugs 21:1075–1087

    Article  CAS  PubMed  Google Scholar 

  43. United States National Library of Medicine (2014) LiverTox clinical clinical and research information on drug-induced liver injury: drug record, alkylating agents

  44. International Myeloma Foundation (2007) Understanding dexamethasone and other steroids

  45. Reeder CB, Reece DE, Kukreti V, Mikhael JR, Chen C, Trudel S, Laumann K, Vohra H, Fonseca R, Bergsagel PL, Leis JF, Tiedemann R, Stewart AK (2014) Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma. Br J Haematol 167:563–565

  46. Stanbury RM, Graham EM (1998) Systemic corticosteroid therapy–side effects and their management. Br J Ophthalmol 82:704–708

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR, Eastern Cooperative Oncology Group (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11:29–37

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  48. Roxane Laboratories (2012) PredniSONE package insert

  49. Richardson PG, Hungria VTM, Yoon S, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa B, Corrado C, San-Miguel JF (2014) Panorama 1: a randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma. ASCO Ann Meet:Abstr 8510

  50. Prince HM, Bishton MJ, Harrison SJ (2009) Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15:3958–3969

    Article  CAS  PubMed  Google Scholar 

  51. Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C, Mukhopadhyay S, Ondovik MS, Khan M, Paley CS, Lonial S (2013) PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 122:2331–2337

  52. Siegel D, Dimopoulos M, Yoon S, Laubach JP, Kaufman JL, Goldschmidt H, Reece D, Leleu X, Durrant S, Offner F, Cavo M, Nagler A, Jagannath S, Houp J, Sun L, Howe J, Wear S, Anderson KC (2012) Vantage 095: final results from a global, single-arm, phase 2B trial of vorinostat in combination with bortezomib in salvage multiple myeloma patients. Eur Hematol Assoc Meet:Abstr 0294

  53. Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KC (2013) Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol 14:1129–1140

    Article  CAS  PubMed  Google Scholar 

  54. Dimopoulos M, Jagannath S, Yoon SS, Siegel DS, Lonial S, Hajek R, Facon T, Rosinol L, Blacklock H, Goldschmidt H, Hungaria V, Spencer A, Palumbo A, Reece D, Graef T, Houp J, Sun L, Eid JE, Anderson KC (2011) VANTAGE 088: an international, multicenter, randomized, double-blind study of vorinostat (MK-0683) or placebo in combination with Bortezomib in patients with multiple myeloma. Blood 118:368–369

    Article  Google Scholar 

  55. Raje N, Hari PN, Vogl DT, Jagannath S, Orlowski RZ, Supko JG, Stephenson P, Jones SS, Wheeler C, Lonial S (2012) Rocilinostat (ACY-1215), a selective HDAC6 inhibitor, alone and in combination with Bortezomib in multiple myeloma: preliminary results from the first-in-humans phase I/II study. ASH Ann Meet:Abstr 4061

  56. Raje N, Vogl DT, Hari PN, Jagannath S, Jones SS, Supko JG, Leone G, Wheeler C, Orlowski RZ, Richardson PG, Lonial S (2013) ACY-1215, a selective histone deacetylase (HDAC) 6 inhibitor: interim results of combination therapy with Bortezomib in patients with multiple myeloma (MM). ASH Ann Meet:Abstr 759

  57. Yee A, Vorhees P, Bensinger WI, Berdeja J, Supko JG, Richardson PG, Jones SS, Patrick G, Wheeler C, Raje N (2013) ACY-1215, a selective histone deacetylase (HDAC) 6 inhibitor, in combination with lenalidomide and Dexamethasone (dex), is well tolerated without dose limiting toxicity (DLT) in patients (Pts) with multiple myeloma (MM) at doses demonstrating biologic activity: interim results of a phase 1b trial. ASH Ann Meet:Abstr 3190

  58. Lonial S, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T, Vij R, Bleickardt E, Reece DE, Benboubker L, Zonder JA, Deng W, Singhal AK, Richardson PGG (2013) Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): updated Ph II results and Ph I/II long-term safety. J Clin Oncol 31:8542, abstract

    Google Scholar 

  59. Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, Kaufman JL, Leleu X, Tsao LC, Westland C, Singhal AK, Jagannath S (2012) Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 30:1953–1959

    Article  CAS  PubMed  Google Scholar 

  60. Plesner T, Lokhorst H, Gimsing P, Nahi H, Lisby S, Richardson PG (2012) Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma - data from a dose-escalation phase I/II study. ASH Ann Meet Abstr 120:73

    Google Scholar 

  61. Plesner T, Arkenau T, Lokhorst H, Gimsing P, Krejcik J, Lemech C, Minnema MC, Lassen U, Cakana A, Brun NC, Basse L, Palumbo A, Richardson P (2013) Preliminary safety and efficacy data of daratumumab in combination with lenalidomide and Dexamethasone in relapsed or refractory multiple myeloma. Blood 122(21):1986, abstract

    Google Scholar 

  62. van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, Lokhorst HM, Mutis T (2011) Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 96:284–290

    Article  PubMed Central  PubMed  Google Scholar 

  63. Martin TG, Strickland SA, Glenn M, Zheng W, Daskalakis N, Mikhael JR (2013) SAR650984, A CD38 monoclonal antibody in patients with selected CD38+ hematological malignancies – data from a dose-escalation phase I study. Blood 122(21):284

    Google Scholar 

  64. Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R, Orlowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M, Lonial S, Jagannath S, Blade J, Miguel JS, Morgan G, Anderson KC, Durie BG, Sonneveld P (2012) Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 26:595–608

    Article  CAS  PubMed  Google Scholar 

  65. Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA (2009) Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 27:3518–3525

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  66. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Blade J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA, International Myeloma Working Group (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22:414–423

    Article  CAS  PubMed  Google Scholar 

  67. Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA (2006) Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 108:403, author reply 404

    Article  CAS  PubMed  Google Scholar 

  68. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR, Eastern Cooperative Oncology Group (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431–436

    Article  CAS  PubMed  Google Scholar 

  69. Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, Testoni N, Tonelli M, de Vivo A, Palareti G, Tura S, Baccarani M (2004) First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89:826–831

    CAS  PubMed  Google Scholar 

  70. Rome S, Doss D, Miller K, Westphal J, Nurse Leadership Board IMF (2008) Thromboembolic events associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs 12:21–28

    Article  PubMed  Google Scholar 

  71. Vij R (2011) Treatment-related adverse events in patients with relapsed/refractory multiple myeloma. Oncology 25(Suppl 2):45–55

  72. Nucci M, Anaissie E (2009) Infections in patients with multiple myeloma. Semin Hematol 46:277–288

    Article  PubMed  Google Scholar 

  73. Mols F, Oerlemans S, Vos AH, Koster A, Verelst S, Sonneveld P, van de Poll-Franse LV (2012) Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry. Eur J Haematol 89:311–319

    Article  PubMed  Google Scholar 

  74. Coleman EA, Goodwin JA, Coon SK, Richards K, Enderlin C, Kennedy R, Stewart CB, McNatt P, Lockhart K, Anaissie EJ, Barlogie B (2011) Fatigue, sleep, pain, mood, and performance status in patients with multiple myeloma. Cancer Nurs 34:219–227

    Article  PubMed Central  PubMed  Google Scholar 

  75. Hanna LR, Avila PF, Meteer JD, Nicholas DR, Kaminsky LA (2008) The effects of a comprehensive exercise program on physical function, fatigue, and mood in patients with various types of cancer. Oncol Nurs Forum 35:461–469

    Article  Google Scholar 

  76. National Comprehensive Cancer Network (2014) Cancer-related fatigue version I. 2014

  77. Smith LC, Bertolotti P, Curran K, Jenkins B, Nurse Leadership Board IMF (2008) Gastrointestinal side effects associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs 12:37–52

    Article  PubMed  Google Scholar 

  78. Wang M, Cheng J (2013) Overview and management of cardiac and pulmonary adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib. Oncology

  79. Chen N, Ye Y, Liu L, Reyes J, Assaf MS, Kasserra C, Zhou S, Palmisano M (2013) Lenalidomide at therapeutic and supratherapeutic doses does not prolong QTc intervals in the thorough QTc study conducted in healthy men. Basic Clin Pharmacol Toxicol 113:179–186

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  80. Colson K (2010) Nursing considerations in the treatment of multiple myeloma. Clin Care Opt

  81. Richardson PG, Laubach JP, Schlossman RL, Mitsiades C, Anderson K (2010) Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. J Natl Compr Cancer Netw 8(Suppl 1):S4–S12

    CAS  Google Scholar 

  82. Niesvizky R, Badros AZ (2010) Complications of multiple myeloma therapy, part 2: risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and anemia. J Natl Compr Cancer Netw 8(Suppl 1):S13–S20

    CAS  Google Scholar 

  83. Kurtin S (2013) Clinical expert commentaries: subcutaneous administration of Bortezomib. Response Assess

  84. Gado K, Domjan G (2013) Quality of life issues of patients with multiple myeloma. InTech open multiple myeloma - a quick reflection on the fast progress:275–288

  85. Bilotti E, Faiman BM, Richards TA, Tariman JD, Miceli TS, Rome SI, International Myeloma Foundation Nurse Leadership Board (2011) Survivorship care guidelines for patients living with multiple myeloma: consensus statements of the international myeloma foundation nurse leadership board. Clin J Oncol Nurs 15(Suppl):5–8

    Article  PubMed Central  PubMed  Google Scholar 

  86. Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV, Rosinol L, Boccadoro M, Cavo M, Lokhorst H, Zweegman S, Terpos E, Davies F, Driessen C, Gimsing P, Gramatzki M, Hajek R, Johnsen HE, Leal Da Costa F, Sezer O, Spencer A, Beksac M, Morgan G, Einsele H, San Miguel JF, Sonneveld P (2011) Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 118:4519–4529

  87. Sharma A, Lokeshwar N (2005) Febrile neutropenia in haematological malignancies. J Postgrad Med 51(Suppl 1):S42–S48

    PubMed  Google Scholar 

  88. Fritz E, Ludwig H, Scheithauer W, Sinzinger H (1986) Shortened platelet half-life in multiple myeloma. Blood 68:514–520

    CAS  PubMed  Google Scholar 

  89. Barkhan P (1974) Blood and neoplastic diseases. Thrombocytopenia. Br Med J 2:324–325

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  90. Enrico O, Gabriele B, Nadia C, Sara G, Daniele V, Giulia C, Antonio S, Mario P (2007) Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol 138:396–397

    Article  PubMed  Google Scholar 

  91. Baxer (2013) Cytoxan package insert

  92. GlaxoSmithKline (2011) ALKERAN package insert

  93. Boehringer-Ingelheim (2007) Dexamethasone package insert

  94. San-Miguel JF, Richardson PG, Gunther A, Sezer O, Siegel D, Blade J, LeBlanc R, Sutherland H, Sopala M, Mishra KK, Mu S, Bourquelot PM, Victoria Mateos M, Anderson KC (2013) Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol 31:3696–3703

    Article  CAS  PubMed  Google Scholar 

  95. Merck (2013) ZOLINZA package insert

  96. Siegel DS, Richardson P, Dimopoulos M, Moreau P, Mitsiades C, Weber D, Houp J, Gause C, Vuocolo S, Eid J, Graef T, Anderson KC (2014) Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood Cancer J 4:e202

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  97. Lokhorst H, Plesner T, Gimsing P, Nahi H, Minnema MC, Lassen U, Krejcik J, Laubach J, Lisby S, Basse L, Richardson P (2013) Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma. J Clin Oncol (suppl;abstr 8512)

Download references

Acknowledgments

William H. Fazzone, PhD, Amanda L. Kauffman, PhD, and Peter J. Simon, PhD, provided medical editorial assistance with this manuscript that was financially supported by Novartis Pharmaceuticals Corporation.

Conflicts of interest

Kathleen Colson consults and serves in an advisory role for Celgene, Millenium, Novartis, and Onyx.

Author information

Authors and Affiliations

  1. Dana-Farber Cancer Institute, 450 Brookline Avenue, Mayer 216, Boston, MA, 02215-5450, USA

    Kathleen Colson

Authors
  1. Kathleen Colson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kathleen Colson.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Colson, K. Treatment-related symptom management in patients with multiple myeloma: a review. Support Care Cancer 23, 1431–1445 (2015). https://doi.org/10.1007/s00520-014-2552-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-014-2552-1

Keywords

Search

Navigation